Clinical trials: Antipsychotics, open to volunteers
NSCLC Adenocarcinoma, Solid Tumor
Atamparib in Patients With Advanced Solid Tumors
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients…
- Trial name
- PARP7 (NCT07374419)
- Testing
- atamparib escalation levels, atamparib RP2D
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Nerviano Medical Sciences (Shanghai) Ltd.
Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain
Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial
The goal of this clinical trial is to learn whether dapagliflozin can help manage weight gain caused by antipsychotic medications in people aged 16 years or older who are receiving antipsychotic treatment and have developed…
- Trial name
- NCT07342764
- Testing
- Dapagliflozin, Metformin, Common Lifestyle Program
- Where
- Oman
- Volunteers
- 110 people
- Sponsor
- Sultan Qaboos University
Schizophrenia
European Long-acting Antipsychotics in Schizophrenia Trial-II
Schizophrenia is a chronic psychiatric illness with a heterogeneous disease course, varying from periods of symptomatic remission to relapse.
- Trial name
- EULAST-II (NCT05165316)
- Where
- Israel
- Volunteers
- 400 people
- Sponsor
- Rene Kahn
Psychiatric Disorder
Antipsychotic Safety and Adherence in Patients With Psychiatric Disorders-An Egyptian Institution-Based Cross-Sectional Study.
This study aims to understand the safety of antipsychotic medications and how consistently patients take these medicines in Egypt.
- Trial name
- NCT07914192
- Volunteers
- 250 people
- Sponsor
- Egyptian Chinese University
Cardiovascular Diseases (CVD), Depression Anxiety Disorder
Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)
Psycho-Cardiological Disease studies the complex links between the cardiovascular system and emotions. The two diseases are now the focus of public health organizations, forming a vicious circle of mutual influence.
- Trial name
- NCT07025590
- Testing
- Moderate-intensity continuous movement and Antipsychotics intervention, Antipsychotics intervention(sertraline, escitalopram, fluoxetine, duloxetine, paroxetine, venlafaxine, and fluvoxamine)
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Guangdong Provincial People's Hospital
Schizophrenia, Antipsychotic Induced Weight Gain
A Relation Between Craving Induction and Treatment Response in Deep Transcranial Magnetic Stimulation (dTMS) for Reducing Antipsychotic-induced Weight Gain in Schizophrenia
Antipsychotic-induced metabolic disturbances, especially weight gain, are common in patients with schizophrenia. Furthermore, it is reported significant changes in food intake happened in patients with weight gain after intaking…
- Trial name
- dTMS (NCT07805980)
- Testing
- Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Active
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Xiangya Hospital of Central South University
Patients Using Olanzapine, Quetiapine, Risperidone or Clozapine
No Guts No Glory Probiotics
The goal of this clinical trial is to learn if probiotics work to prevent or reduce metabolic side effects caused by antipsychotic medication in adults.
- Trial name
- NGNGP (NCT07606014)
- Testing
- Probiotic Formula
- Where
- 3 sites in Netherlands
- Volunteers
- 112 people
- Sponsor
- University Medical Center Groningen
Schizophrenia
A Study of the Efficacy of Fecal Microbiota Transplantation(FMT) in the Treatment of Schizophrenia
The purpose of this study was to explore whether repeated oral fecal capsules could improve outcomes in patients with schizophrenia receiving conventional antipsychotic drugs.
- Trial name
- NCT05850585
- Testing
- Fecal microbiota transplantation(FMT)
- Volunteers
- 100 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Extrapyramidal Symptoms, Drug-induced Parkinsonism
A Computer-Assisted Tool for Objective Assessment of Extrapyramidal Symptoms
This prospective, single-center observational study aims to develop and validate a computer-assisted tool for the objective quantitative assessment of extrapyramidal symptoms (EPS).
- Conditions
- Extrapyramidal Symptoms, Drug-induced Parkinsonism, Akathisia, Drug-Induced, Tardive Dyskinesia (TD)
- Trial name
- NCT07715994
- Testing
- Computer-Assisted Objective Assessment of Extrapyramidal Symptoms
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Psychosis
Strategic Timing of Resistance Training to Guard Against Antipsychotic-Induced Metabolic Syndrome
This study is evaluating whether a supervised resistance training (strength training) programme is feasible to perform in a first-episode psychosis service.
- Trial name
- START GAAIMS (NCT07386483)
- Testing
- Resistance training programme
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- University College Dublin
Schizophenia Disorder, Schizoaffective Disorder
Exercise and Olanzapine-samidorphan
This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic…
- Conditions
- Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
- Trial name
- NCT06740890
- Testing
- Olanzapine-samidorphan + exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute…
- Trial name
- NOVA2 (NCT07363577)
- Testing
- LB-102 (50 mg tablet), LB-102 (100 mg tablet)
- Where
- 13 sites in United States
- Volunteers
- 456 people
- Sponsor
- LB Pharmaceuticals Inc.
Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients
Olanzapine is a thieno-benzodiazepine derivate that is effective managing the symptoms of schizophrenia and reducing the psychopathological symptoms of psychosis.
- Trial name
- NCT05669742
- Testing
- Empagliflozin, olanzapine
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Tanta University
Schizophrenia Disorder, Schizoaffective Disorder
Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization
This study is a randomized controlled trial evaluating the impact of financial incentives on medication adherence among individuals with schizophrenia, schizoaffective disorder, or bipolar disorder and/or co-occurring substance…
- Conditions
- Schizophrenia Disorder, Schizoaffective Disorder, Bipolar Disorder (BD), Substance Use Disorder (SUD)
- Trial name
- NCT07130500
- Testing
- Financial incentives for adherence to long-acting injectable medication, Standard of care with monthly surveys
- Where
- 6 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Stanford University
Negative Symptoms of Schizophrenia
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate…
- Trial name
- NCT07565428
- Testing
- Roluperidone, risperidone, aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 380 people
- Sponsor
- Minerva Neurosciences
Schizophrenia
Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia
To evaluate the efficacy of Paliperidone Palmitate Injection in replacing oral antipsychotics for the treatment of schizophrenia and its impact on social function
- Trial name
- NCT07075237
- Testing
- Paliperidone Palmitate Injection (PP1M)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Province Nanjing Brain Hospital
Scizophrenia
Carbergoline for Antipsychotic Induced Hyperprolactinemia.
The goal of this clinical trial is to learn if cabergoline is safe to use in patients with antipsychotic-induced hyperprolactinemia in adults with scizophrenia.
- Trial name
- NCT07386080
- Testing
- Cabergoline (Dopamine Agonist)
- Where
- Denmark
- Volunteers
- 146 people
- Sponsor
- Zealand University Hospital
Schizophrenia, Schizoaffective Disorder
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia
- Trial name
- NCT03495024
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Psychosis; Acute
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and…
- Trial name
- CINEMA (NCT07483294)
- Testing
- risperidone, aripiprazole
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Northwell Health
Severe Mental Disorder, Metabolic Complication
Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic
This study will examine the effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness
- Conditions
- Severe Mental Disorder, Metabolic Complication, Side-Effect;Medication, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT06624462
- Testing
- Treatment in the Meta Care Clinic, Standard care with general practitioner and/or outpatient clinics
- Where
- Denmark
- Volunteers
- 84 people
- Sponsor
- Bjorn H. Ebdrup